Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 2352Neoplasms 1707Prostatic Neoplasms 1197Lung Neoplasms 923Colorectal Neoplasms 882Carcinoma, Non-Small-Cell Lung 867Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 577Multiple Myeloma 549Carcinoma, Hepatocellular 516Brain Neoplasms 513Neoplasm Metastasis 459Head and Neck Neoplasms 454Melanoma 414Ovarian Neoplasms 413Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 375Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 361Rectal Neoplasms 341Recurrence 336Sarcoma 325Hematologic Neoplasms 323Colonic Neoplasms 323Lymphoma 319Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 278

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-Malignant Neoplasm × 1 year × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡